Back
  1. Home
  2. Profile of Joséphine MULLER (ULiège)
Profil

MULLER Joséphine

Département de médecine interne > Service d'hématologie clinique

See author's contact details
Main Referenced Co-authors
Caers, Jo  (33)
Beguin, Yves  (32)
Heusschen, Roy  (29)
Binsfeld, Marilène  (16)
Baron, Frédéric  (15)
Main Referenced Keywords
bone disease (10); multiple myeloma (10); saracatinib (6); SRC kinase (6); GVHD (3);
Main Referenced Unit & Research Centers
GIGA-I3 - Giga-Infection, Immunity and Inflammation - ULiège (2)
Main Referenced Disciplines
Hematology (21)
Biochemistry, biophysics & molecular biology (19)

Publications (total 39)

The most downloaded
2071 downloads
CAERS, J., Binsfeld, M., Muller, J., Heusschen, R., & Beguin, Y. (2014). Gammapathie monoclonale de signification indéterminée : information destinée aux médecins référents. Revue Médicale de Liège, 69, 41-46. https://hdl.handle.net/2268/172664

The most cited

129 citations (OpenAlex)

Faict, S., Muller, J., De Veirman, K., De Bruyne, E., Maes, K., Vrancken, L., Heusschen, R., De Raeve, H., Schots, R., Vanderkerken, K., Caers, J., & Menu, E. (2018). Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer Journal, 8 (11), 105. doi:10.1038/s41408-018-0139-7 https://hdl.handle.net/2268/233062

Lombardo, G., LECHANTEUR, C., BRIQUET, A., Seidel, L., Willems, E., Servais, S., BAUDOUX, E., Kerre, T., Zachee, P., HERMAN, J., JANSSEN, A., MULLER, J., Baron, F., & Beguin, Y. (03 December 2024). Co-infusion of mesenchymal stromal cells to prevent GVHD after allogeneic hematopoietic cell transplantation from HLA-mismatched unrelated donors after reduced-intensity conditioning: a double-blind randomized study and literature review. Stem Cell Research and Therapy, 15 (1), 461. doi:10.1186/s13287-024-04064-w
Peer Reviewed verified by ORBi

Vande Catsyne, C.-A., Sayyed, S. A., Molina Ortiz, P., Moës, B., Communi, D., Muller, J., Heusschen, R., CAERS, J., Azzi, A., Erneux, C., & Schurmans, S. (2020). Altered chondrocyte differentiation, matrix mineralization and MEK-Erk1/2 signaling in an INPPL1 catalytic knock-out mouse model of opsismodysplasia. Advances in Biological Regulation, 76, 100651. doi:10.1016/j.jbior.2019.100651
Peer Reviewed verified by ORBi

Muller, J. (2018). Molécules ciblant les interactions entre cellules myélomateuses et ostéoclastes [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/222964

Ehx, G., SOMJA, J., Warnatz, H.-J., Ritacco, C., HANNON, M., Delens, L., Fransolet, G., DELVENNE, P., Muller, J., BEGUIN, Y., Lehrach, H., Belle, L., Humblet-Baron, S., & BARON, F. (2018). Xenogeneic graft-versus-host disease in humanized NSG and NSG-HLA-A2/HHD mice. Frontiers in Immunology, 9, 1943. doi:10.3389/fimmu.2018.01943
Peer Reviewed verified by ORBi

Muller, J., Bolomsky, A., Dubois, S., Duray, E., Stangelberger, K., Plougonven, E., Lejeune, M., Léonard, A., Marty, C., Hempel, U., Baron, F., BEGUIN, Y., Cohen-Solal, M., Ludwig, H., Heusschen, R., & CAERS, J. (2018). Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity on multiple myeloma bone disease. Haematologica, 103, 1359-1368. doi:10.3324/haematol.2017.185397
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Duray, E., WITHOFS, N., Bolomsky, A., Baron, F., Beguin, Y., Menu, E., Ludwig, H., & Caers, J. (2018). Molecular mechanisms, current management and next generation therapy in myeloma bone disease. Leukemia and Lymphoma, 59, 14-28. doi:10.1080/10428194.2017.1323272
Peer Reviewed verified by ORBi

Vrancken, L., Muller, J., Lejeune, M., Grégoire, C., Delens, L., Jaspers, A., Servais, S., DE PRIJCK, B., Baron, F., Caers, J., & Beguin, Y. (2018). Nouveautes dans la prise en charge du myelome. Revue Médicale Suisse, 14 (615), 1438-1442.
Peer Reviewed verified by ORBi

Bolomsky, A., Heusschen, R., Schlangen, K., Stangelberger, K., Muller, J., Schreiner, W., Zojer, N., Caers, J., & Ludwig, H. (2018). Maternal embryonic leucine zipper kinase is a novel target for proliferation associated high-risk myeloma. Haematologica, 103, 325-335. doi:10.3324/haematol.2017.172973
Peer Reviewed verified by ORBi

Faict, S., Muller, J., De Veirman, K., De Bruyne, E., Maes, K., Vrancken, L., Heusschen, R., De Raeve, H., Schots, R., Vanderkerken, K., Caers, J., & Menu, E. (2018). Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer Journal, 8 (11), 105. doi:10.1038/s41408-018-0139-7
Peer Reviewed verified by ORBi

Ehx, G., SOMJA, J., Fransolet, G., Delens, L., Muller, J., BEGUIN, Y., Humblet-Baron, S., Hannon, M., & BARON, F. (10 February 2017). Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice [Poster presentation]. 32nd General Annual Meeting of the Belgian Hematological Society, Bruxelles, Belgium.

Heusschen, R., Bolomsky, A., Schlangen, K., Schonfelder, K., Muller, J., Shreiner, W., Zojer, N., CAERS, J., & Ludwig, H. (February 2017). Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an attractive Novel Drug Target in Multiple Myeloma and its associated Bone Disease [Paper presentation]. 32nd General Annual Meeting of the Belgian Hematological Society.

Ehx, G., SOMJA, J., Delens, L., Fransolet, G., DELVENNE, P., Muller, J., BEGUIN, Y., Hannon, M., Humblet-Baron, S., & BARON, F. (01 February 2017). Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice [Paper presentation]. GIGA-Day 2017: New insights into the hallmark of cancer, Liège, Belgium.
Peer reviewed

Heusschen, R., Muller, J., WITHOFS, N., BARON, F., BEGUIN, Y., & CAERS, J. (2017). Multiple myeloma bone disease: from mechanisms to next generation therapy. Belgian Journal of Hematology, 8, 66-74.
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Bolomsky, A., Ludwig, H., & CAERS, J. (2017). Maternal Embryonic Leucine Zipper Kinase (MELK) is a key player and an attractive novel target in proliferation-associated high risk multiple myeloma [Paper presentation]. Meeting of the Austrian Society for Hematology and Oncology 2017.

Heusschen, R., Muller, J., Bolomsky, A., Schonfelder, K., Plougonven, E., Léonard, A., BEGUIN, Y., Cohen-Solal, M., Heinz, L., & CAERS, J. (2017). Maternal Embryonic Leucine Zipper Kinase (MELK) inhibition has direct effects on bone cells and prevents the development of osteolytic bone disease in multiple myeloma [Paper presentation]. 44th Annual European Calcified Tissue Society Congress.

Muller, J., BINSFELD, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (2017). Galectin-1 decreases during osteoclast formation [Poster presentation]. 44th Annual European Calcified Tissue Society Congress, Austria.

Ehx, G., Somja, J., Fransolet, G., Delens, L., Muller, J., Beguin, Y., Humblet-Baron, S., & Baron, F. (14 October 2016). Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice [Poster presentation]. Regulatory T cells mini-symposium, Leuven, Belgium.

Fransolet, G.* , Ehx, G.* , SOMJA, J., Delens, L., Hannon, M., Muller, J., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., DELVENNE, P., BEGUIN, Y., Conteduca, G.* , & BARON, F.*. (04 July 2016). Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. Journal of Hematology and Oncology, 9, 53. doi:10.1186/s13045-016-0281-2
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (28 February 2016). Galectin-1 is involved in osteoclast biology [Poster presentation]. 2nd Herbert Fleisch Workshop, Brugge, Belgium.

Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. Belgian Journal of Hematology.
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). The Src Inhibitor AZD0530 Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma [Poster presentation]. 43rd Annual European Calcified Tissue Society Congress, Rome, Italy.

Binsfeld, M., Muller, J., Lamour, V., De Veirman, K., De Raeve, H., Bellahcene, A., Van Valckenborgh, E., BARON, F., BEGUIN, Y., CAERS, J., & Heusschen, R. (2016). Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. Oncotarget, 7, 37931-37943. doi:10.18632/oncotarget.9270
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., BEGUIN, Y., Poirier, F., Cohen-Solal, M., Thijssen, V., & CAERS, J. (2016). Galectin-1 attenuates bone resorption by osteoclasts [Poster presentation]. EMBO Workshop: Transducing glycan information into function: Lessons from galectins.

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (2016). Galectin-1 is involved in osteoclast biology [Poster presentation]. 43rd Annual European Calcified Tissue Society Congress, Rome, Italy.

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma [Poster presentation]. GIGA day 2016, Liège, Belgium.

Bolomsky, A., Heusschen, R., Schlangen, K., Schönfelder, K., Muller, J., Schreiner, W., Zojer, N., CAERS, J., & Ludwig, H. (2016). Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an attractive Novel Drug Target in Multiple Myeloma. Blood.
Peer Reviewed verified by ORBi

Heusschen, R.* , Muller, J.* , Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., BEGUIN, Y., Menu, E., Cohen-Solal, M., & CAERS, J. (2016). SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma. Oncotarget, 7, 30712-30729. doi:10.18632/oncotarget.8750
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma [Paper presentation]. 31st General Annual Meeting of the Belgian Hematological Society, Brussels, Belgium.

Heusschen, R., Muller, J., Fillet, M., Vanderkerken, K., Thijssen, V., Cohen-Solal, M., BEGUIN, Y., & CAERS, J. (2016). Lectin-glycoprotein interactions in the diagnosis and biology of myeloma-related bone disease [Poster presentation]. 2nd Herbert Fleisch Workshop of the International Bone and Mineral Society, Brugge, Belgium.

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma. Blood.
Peer Reviewed verified by ORBi

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., Beguin, Y., Heusschen, R., & CAERS, J. (2015). The anti-angiogenic peptide Anginex blocks osteoclastogenesis. Belgian Journal of Hematology, Abstracts book.
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma. Blood, 126 (23), 3018.
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma [Poster presentation]. 57th ASH Annual Meeting and Exposition, Orlando, United States - Florida.

Binsfeld, M., Fostier, K., Muller, J., Baron, F., Schots, R., Beguin, Y., Heusschen, R., & CAERS, J. (2014). Cellular immunotherapy in multiple myeloma : lessons from preclinical models. Biochimica et Biophysica Acta. Reviews on Cancer, 1846, 392-404. doi:10.1016/j.bbcan.2014.08.001
Peer Reviewed verified by ORBi

Heusschen, R., Schulkens, I., Muller, J., Griffioen, A., BEGUIN, Y., Thijssen, V., & CAERS, J. (2014). Galectins in cancer: jacks of all trades [Paper presentation]. 19th World Congress on Advances in Oncology, Athens, Greece.

Heusschen, R., Muller, J., Binsfeld, M., Thijssen, V., BEGUIN, Y., & CAERS, J. (2014). Galectin expression in the multiple myeloma microenvironment [Poster presentation]. GIGA day 2014, Liège, Belgium.

CAERS, J., Binsfeld, M., Muller, J., Heusschen, R., & Beguin, Y. (2014). Gammapathie monoclonale de signification indéterminée : information destinée aux médecins référents. Revue Médicale de Liège, 69, 41-46.
Peer reviewed

Heusschen, R., Schulkens, I., Muller, J., Griffoen, A., Beguin, Y., Thijssen, V., & CAERS, J. (2014). Galectins in cancer: jacks of all trades. International Journal of Molecular Medicine.
Peer Reviewed verified by ORBi

Muller, J., CAERS, J., Binsfeld, M., Dubois, S., Carmeliet, G., BEGUIN, Y., & Heusschen, R. (2014). Galectin expression in the multiple myeloma microenvironment. Belgian Journal of Hematology.
Peer Reviewed verified by ORBi

Contact ORBi